Economic burden of long-term treatment of severe fecal incontinence.

Colostomy Colostomía Costes medicos Economic impact Fecal incontinence Impacto económico Incontinencia fecal Medical costs Neuroestimulacion de raíces sacras Sacral nerve stimulation Symptomatic treatment Tratamiento sintomático

Journal

Cirugia espanola
ISSN: 2173-5077
Titre abrégé: Cir Esp (Engl Ed)
Pays: Spain
ID NLM: 101771152

Informations de publication

Date de publication:
Jul 2022
Historique:
received: 28 01 2021
accepted: 14 04 2021
pubmed: 11 5 2022
medline: 29 6 2022
entrez: 10 5 2022
Statut: ppublish

Résumé

Find out the long-term economic cost associated with the treatment of severe fecal incontinence by SNS versus symptomatic conservative treatment and definitive colostomy. Detailed descriptive study of the costs of the healthcare process (interventions, consultations, devices, complementary tests, hospitalization, etc.) of 3 treatment alternatives for fecal incontinence using analytical accounting tools of the Health Service based on clinical activity data. The frequency of use of health resources or the quantity of products dispensed in pharmacies (medication, diapers, ostomy material, etc.) was estimated in each case. Costs derived from adverse situations were included. Patients with severe fecal incontinence, defined by a score greater than 9 on the Wexner severity scale, in whom first-line treatments had failed, were included. Data from a consecutive cohort of 93 patients who underwent an SNS between 2002 and 2016 were used; patients who underwent definitive colostomy (n=2); parastomal hernia (n=3); and colostomy stenosis (n=1). The mean cumulative cost in 10 years per patient in each alternative was: € 10,972.9 symptomatic treatment (62% diapers); € 17,351.57 SNS (95.83% interventions; 81.6% devices); € 25,858.54 definitive colostomy (70.4% ostomy material and accessories). Management of severe fecal incontinence implies a great burden in economic terms. The colostomy is the alternative that generates the most direct cost, followed by SNS and symptomatic treatment.

Identifiants

pubmed: 35537695
pii: S2173-5077(22)00114-4
doi: 10.1016/j.cireng.2022.05.006
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

422-430

Informations de copyright

Copyright © 2021 AEC. Published by Elsevier España, S.L.U. All rights reserved.

Auteurs

Mario Javier de Miguel Valencia (MJ)

Servicio Cirugía General, Hospital Reina Sofía, Tudela, Navarra, Spain. Electronic address: mariodemiguel85@gmail.com.

Alberto Margallo Lana (A)

Servicio de Control y Análisis del Coste, Departamento de Salud del Gobierno de Navarra, Pamplona, Navarra, Spain.

M Ángeles Pérez Sola (MÁ)

Servicio Cirugía General, Hospital Reina Sofía, Tudela, Navarra, Spain.

Eduardo Sánchez Iriso (E)

Departamento de Economía, Área de Economía Aplicada, Universidad Pública de Navarra, Pamplona, Navarra, Spain.

Juan Manuel Cabasés Hita (JM)

Departamento de Economía, Área de Economía Aplicada, Universidad Pública de Navarra, Pamplona, Navarra, Spain.

Iñaki Alberdi Ibáñez (I)

Servicio Cirugía General, Hospital Reina Sofía, Tudela, Navarra, Spain.

Miguel Ángel Ciga Lozano (MÁ)

Unidad Cirugía Colorrectal, Complejo Hospitalario Navarra, Pamplona, Navarra, Spain.

Mario de Miguel Velasco (M)

Unidad Cirugía Colorrectal, Complejo Hospitalario Navarra, Pamplona, Navarra, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH